Sign In
Buy NKTX
$2.72
-0.190 (-6.53%)
At Close: Jun 03, 2026
Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Wednesday, 19'th Mar 2025
Nkarta (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
Nkarta to Participate in March Investor Conferences
08:01am, Tuesday, 25'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its pa
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
06:01am, Thursday, 05'th Dec 2024
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts
Nkarta to Participate in an Upcoming Investor Conference
07:02am, Tuesday, 26'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its pa
Nkarta to Participate in an Upcoming Investor Conference
08:02am, Tuesday, 12'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its pa
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
04:02pm, Thursday, 07'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today r
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
09:07am, Tuesday, 08'th Oct 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Nkarta to Participate in Upcoming Investor Conference
04:01pm, Tuesday, 03'rd Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its p
Why Nkarta Stock Is Soaring Today
12:37pm, Wednesday, 14'th Aug 2024
Raymond James upgraded Nkarta stock from outperform to a strong buy. The investment firm likes the biopharma's cash position and the opportunities for its lead candidate NKX019.
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
09:03pm, Tuesday, 13'th Aug 2024
This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three d
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
04:01pm, Tuesday, 13'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today r
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
06:01am, Tuesday, 16'th Jul 2024
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced change
Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know
01:00pm, Wednesday, 10'th Jul 2024
Nkarta (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 Undervalued Stocks Primed for a 2X Return
10:20am, Monday, 01'st Jul 2024
For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a shar
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
